New Delhi: Panacea Biotec has supplied the first shipping second component of the Russian V Sputnik Vaccine produced by TI for sale in India.
This is the first batch of the second component produced and supplied by companies in India, a drug company and Russian direct investment fund (RDIF) said in a joint statement.
Sputnik V has pioneered the use of heterogeneous enhancers (two different vectors for two shots in the path of vaccination between the covid vaccine).
This approach provides immunity with a duration of longer than vaccines using the same shipping mechanism for both shots, the statement said.
The second component of Sputnik V has been produced at the company vaccine manufacturing facility at Himachal Pradesh, Panacea Biotec said in submitting regulations late at night on Monday.
Batch will be distributed in India through Dr.
Reddy Laboratory, RDIF Partners and Panacea Biotec, he added.
“Panacea Biotec is happy to produce and send the first batch of component II (AD5) Sputnik Vaccine V.
More batches are currently producing in our manufacturing facilities at Himachal Pradesh,” Panacea Biotec said MD Rajesh Jain.
Sputnik V vaccine has been developed by Gamaleya National Research Center of Epidemiology and Microbiology and RDIF.
Panacea Biotec shares traded at Rs 312.00 per script in BSE, up 5.91 percent from the previous closure.